The combination of VISTA and PD-L1 antibodies substantially strengthened the therapeutic impact in a mouse colon cancer model, and since VISTA and PD-L1 have different mechanisms, immune checkpoint combinations might also be a potential therapeutic approach in the treatment of PDAC [132]. The gene discussed is CD274; the disease is malignant colon neoplasm.